Adjunctive duration-doubled transcranial direct current stimulation for the treatment of depressive patients with suicidal ideation: study protocol for a double-blind, randomized, sham-controlled trial

Yiming Chen, Dongbin Lyu, Fan Wang, Qinte Huang, Weichieh Yang, Mengke Zhang, Zheyi Wei, Shuxiang Shi, Shuqi Kong, Shentse Chen, Shuang He, Vivien Yang, Yiru Fang, Abdel Douiri, Wu HongTrials 2024 · DOI

TL;DR

This paper outlines a study protocol for a novel treatment approach for major depressive disorder (MDD) with suicidal ideation. The study investigates whether doubling the duration of transcranial direct current stimulation (tDCS) can rapidly reduce suicidal thoughts and improve depressive symptoms, potentially offering a new avenue for treatment beyond traditional methods.

What Problem Does This Paper Address?

Suicidal ideation is a critical and often urgent symptom in individuals with Major Depressive Disorder (MDD). While existing treatments like pharmacotherapy and psychotherapy are valuable, there's a pressing need for interventions that can rapidly alleviate suicidal thoughts, especially in acute situations. Transcranial direct current stimulation (tDCS) has shown promise as a treatment for MDD, but its efficacy in rapidly reducing suicidal ideation, particularly with optimized stimulation parameters, remains an area requiring further investigation. This study aims to fill this gap by exploring a "duration-doubled" tDCS protocol as an adjunctive therapy for this specific patient population.

Methods

This study employs a double-blind, randomized, sham-controlled trial design. Seventy-six MDD patients with suicidal ideation will be randomly assigned to one of two groups:

  • Active tDCS group: Receives 60-minute sessions of tDCS.
  • Sham tDCS group: Receives a sham stimulation designed to mimic the initial sensations of active tDCS.

The tDCS electrodes (anode and cathode) will be placed over the left and right dorsolateral prefrontal cortex (DLPFC), respectively. Participants will undergo 10 daily sessions over two weeks. The primary outcome measure is the change in the Beck Scale for Suicide Ideation (BSI) score after 5 and 10 sessions. Secondary outcomes include changes in other clinical assessments (e.g., Hamilton Depression Rating Scale - HAMD-17) and the analysis of blood biomarkers related to inflammation and neurotrophic factors, which may serve as predictors of treatment response or suicide risk.

Datasets

Not discussed in the paper.

Key Insights and Ideas

  • Doubling tDCS duration as a novel strategy: The core innovation is investigating whether extending the tDCS session duration from the typical 30 minutes to 60 minutes can lead to more rapid and pronounced therapeutic effects, particularly for suicidal ideation.
  • Focus on rapid reduction of suicidal ideation: Unlike many previous studies that treated suicidal ideation as a secondary outcome, this trial prioritizes it as the primary endpoint, reflecting the urgent need for interventions that can quickly address this critical symptom.
  • Biomarker exploration for personalized treatment: The study's inclusion of blood biomarkers (e.g., inflammatory markers like CRP, NLR, and neurotrophic factors like BDNF) is crucial. Identifying biomarkers that correlate with treatment response could pave the way for more personalized and effective interventions in the future.
  • Rigorous methodology: The use of a double-blind, sham-controlled design, randomization via REDCap, and blinding of participants, care providers, and assessors are strong methodological choices aimed at minimizing bias and ensuring the reliability of the findings.

Key Results

As this is a study protocol, no results are available yet. The study is currently in the enrollment stage, with recruitment expected to be completed by March 2024.

Limitations and Future Work

The authors acknowledge several limitations:

  • Participant compliance for outpatients: Outpatients will need to travel daily to the hospital for treatment, which could pose a burden and potentially lead to missed sessions, especially for those with severe depression. The authors suggest that home-based tDCS could be explored in future studies.
  • Blinding effectiveness: While the study employs standard blinding procedures, recent evidence suggests that the sham stimulation method used might not be sufficiently effective in blinding participants, potentially influencing the placebo effect. Further research into alternative blinding methods is recommended.

Future work could involve exploring home-based tDCS, refining blinding techniques, and leveraging the collected biomarker data to develop predictive models for treatment response and suicide risk. The study also aims to build a database of anonymized recordings for future analyses, which could be valuable for the broader research community.

Summary updated

Abstract

The trial protocol is registered with ClinicalTrials.gov under protocol registration number NCT05555927. Registered on September 25, 2022.
BibTeX
@inproceedings{chen2024adjunctive,
  author = {Yiming Chen and Dongbin Lyu and Fan Wang and Qinte Huang and Weichieh Yang and Mengke Zhang and Zheyi Wei and Shuxiang Shi and Shuqi Kong and Shentse Chen and Shuang He and Vivien Yang and Yiru Fang and Abdel Douiri and Wu Hong},
  title = {{Adjunctive duration-doubled transcranial direct current stimulation for the treatment of depressive patients with suicidal ideation: study protocol for a double-blind, randomized, sham-controlled trial}},
  booktitle = {Trials},
  year = {2024},
  doi = {10.1186/s13063-023-07858-0},
}
Figure